Ladder Bio

Executive Summary

Ladder Bio is a privately held biotechnology company founded in 2020 and headquartered in Cambridge, MA. The company is pioneering a novel class of synthetic therapeutics known as Spiroligomer™ molecules—modular, fused-ring structures that combine the target selectivity of biologics with the drug-like properties of small molecules. By leveraging its proprietary chemical platform, Ladder Bio is creating libraries of billions of compounds for targeted drug discovery and diagnostic applications. The company's approach has the potential to unlock new therapeutic modalities for diseases where traditional small molecules or biologics fall short, though it remains in the early stages of platform validation.

Upcoming Catalysts (preview)

• Q3 2026Lead Optimization of First-In-Class Spiroligomer Candidate40% success
• Q4 2026Publication of Preclinical Proof-of-Concept Data60% success
• H1 2027Series A or B Financing Round50% success